Avosentan
Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure[1][2][3][4].
Product Specifications
CAS Number
[290815-26-8]
Product Name Alternative
Ro 67-0565; SPP-301
UNSPSC
12352005
Hazard Statement
H315, H319, H335, H413
Target
Endothelin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/avosentan.html
Concentration
10mM
Purity
98.15
Solubility
DMSO : 6.67 mg/mL (ultrasonic)
Smiles
COC1=C(OC(C(NS(C2=NC=C(C=C2)C)(=O)=O)=NC(C3=CC=NC=C3)=N4)=C4OC)C=CC=C1
Molecular Formula
C23H21N5O5S
Molecular Weight
479.51
Precautions
H315, H319, H335, H413
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
ETA
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items